Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02108652 · OUTCOME

Percentage of Participants Alive at 1-year

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) · Source last updated 2024-03-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
1-year

Analysis population: Cohort 2 ITT Population

Groups in this outcome

Cohort 2: Participants With Second-line or Beyond Treatments

Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 2: Participants With Second-line or Beyond Treatments310

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort 2: Participants With Second-line or Beyond Treatments36.9Not reported31.442.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        31.4
        upper Limit
        42.3
        value
        36.9
denoms
  1. counts
    1. group Id
      OG000
      value
      310
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
    id
    OG000
    title
    Cohort 2: Participants With Second-line or Beyond Treatments
param Type
NUMBER
population Description
Cohort 2 ITT Population
reporting Status
POSTED
time Frame
1-year
title
Percentage of Participants Alive at 1-year
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice